<DOC>
	<DOC>NCT00846274</DOC>
	<brief_summary>To evaluate the PK/PD of single injected human ATIII Products, SKATIII and ATIII, phase1 study in healthy male subjects was designed</brief_summary>
	<brief_title>Phase1 Syudy to Evaluate the Safety and PK/PD of Human Antithrombin III</brief_title>
	<detailed_description />
	<mesh_term>Antithrombins</mesh_term>
	<mesh_term>Antithrombin III</mesh_term>
	<criteria>ages 19 to 40 Body weight: More than 50kg Healthy male subject Hb&lt;14g/dL, Hct&lt;42% ATIII hypersensitivity</criteria>
	<gender>Male</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>Healthy Male subjects</keyword>
</DOC>